ACHV - Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference | Benzinga
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024.
The Achieve corporate presentation will be included in the "Digital & Public Health" Session and is scheduled for 1:50 P.M. PDT on Thursday, April 18, 2024. For additional information and to register, please visit Life Science Innovation Northwest 2024.
About Achieve and Cytisinicline?
Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3
In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping.3?In 2023, approximately 2.1 million middle and high school students in the United States reported using e-cigarettes.4 Currently, there ...